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CASE REPORT
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are a rare
neoplasms arising from connective tissue elements of
the gastrointestinal wall. They show a great heterogenity
with respect to their histogenetic, morphologic and
prognostic characteristics.1
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ABSTRACT
Gastrointestinal stromal tumors (GIST) are rare tumors of the gastrointestinal (GI) tract that arise from
primitive mesenchymal cells. GISTs occur throughout the GI tract but are usually located in the stomach
and small intestine. GISTs are known with myoid, neural or mixed features of differentiation. Clinical
findings are gastrointestinal bleeding, abdominal pain, and weight loss. GISTs express a heterogeneous
clinical course not easily predicted. The histologic features that correlate best with development of
recurrence and metastasis are mitotic activity, tumor size and the presence of tumor necrosis and most
recently, mutation in the c-kit gene. Some authors specifically use the term GIST to refer to only those
mesenchymal tumors that express CD117, whereas others believe that the diagnosis can be made in
the absence of CD117 positivity based on clinical and morphologic features. Surgical resection remains
the treatment of choice, since chemotherapy and radiation are ineffective. Long-term follow-up is
imperative and recurrence rates are high.
We report the case of a 60 years old female patient who presented with intermittent melena, chronic
dyspepsia, and anemia. Upper digestive tract endoscopy showed a submucosal tumor, broad-based,
centrally ulcerated, projection of >5 cm in the gastric corpus-antral wall as the cause of the upper
gastrointestinal bleeding. Endoscopic biopsies were negative for neoplastic changes. After triple
eradication therapy of Helicobacter pylori and treatment continued with proton pump inhibitor agent,
the patient underwent distal gastrectomy with Billroth-I reconstruction. Histopatological studies on the
surgical resection specimen revealed a GIST of smooth muscle with spindle cell, no evidence of mitotic
activity but of uncertain biological behavior. One year after surgery the patient is was improved with no
signs of residual malignancy. However, metastases were found later in the liver in the next two year.
Keywords: GIST, stromal tumor, surgery, C-kit.
GISTs account for approximately 80% of
gastrointestinal (GI) mesenchymal tumors, in benign
or malignant form. These tumors predominantly affect
middle-aged and older patients with a median age of
50-60 years, with an equal sex incidence. About
60-70% of GISTs occur in the stomach, 20-30% in the
small intestine and 10% or less in the oesophagus.2,3
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The annual incidence of clinically detected new
cases of GIST in the United States have increased
from perhaps 300-500 per year to 5,000-6,000 per year
due to renewed interest and better diagnosis. In Finnland
suggest that the annual incidence of all GISTs is
approximately 10-20/million and that of malignant GISTs
is about 4 cases per million of population.2
The immunophenotypic and ultra-structural
resemblance of GISTs to the interstitial cells of Cajal,
gastrointestinal pacemaker cells which control gut
motility, suggests a histogenesis from the latter cells. 2,3,4
The term of GISTs was introduced and used in 1983,
most tumors described as leiomyomas and
leiomyosarcomas in the older medical literature
actually refer to GISTs. Only with tumors in
the esophagus does the term leiomyoma/
leiomyosarcomas remain accurate.3,5,6
These tumors have a wide clinical spectrum at
presentation. They range from incidentally detected,
asymptomatic, benign GISTs to large malignant tumors
and if symptomatic, GISTs usually cause symptoms as
a result of their size or tendency to ulcerate and bleed.
The most common presenting signs and symptoms
include abdominal pain, GI bleeding manifested by
hematemesis or melena, and a palpable mass with
weight loss.7,8,9
Microscopically, there are two principal
histological patterns:  spindle cell (70-80% of cases) or
epithelioid (30-40% of cases) character, or a
combination of both in variable proportions. GISTs are
immunohistochemically positive for c-kit protein
(CD117) and/or CD34.6,10
The expression of CD117 (a proto-oncogene
protein) has emerged as the most important defining
feature and probably the gold standard for diagnosing
GISTs.6,9,11
Complete surgical excision is the treatment of choice
for localized GISTs. Inoperable and metastasis targeted
therapy using imatinib mesylate is a synthetic tyrosine
kinase inhibitor, which now has been confirmed by
larger trials in America and in Europe. This drug has
effect as proapoptotic and antiproliferation. The role
of radiother-apy is limited by the potential toxicity to
surrounding struc-tures, especially the intestines. In the
other hand conventional chemotherapy is usually  not
responsive.2,5,12
The histologic features that correlate best with
development of recurrence and metastasis include
 mitotic activity, tumor size and the presence of tumor
necrosis and most recently, mutation in the c-kit gene.
Long-term follow-up is imperative, as recurrence rates
are high.3,13,14
We report a case diagnosed as GIST a rare
neoplasm presenting with gastrointestinal bleeding.
CASE REPORT
Mrs. A, 60 years old, with chief complaint
intermittent melena for 5 years and received blood
transfusion for several times. She have visited many
physicians before, and being diagnosed gastric ulcer.
She was  treated with antacid. Beside that, she always
felt abdominal fullness, sometimes with nausea and
vomiting, pain in epigastrium, anorexia, and weight loss
15 kg of body weight five years period. The patient
frequently feelt weak and dizziness. There was no
history of taking NSAID, jaundice, and malignancy in
family. She had hypertension for 5 years and taking
antihypertensive medicine regularly.
Physical examination on admission revealed
the general condition was moderately ill with poor
nutritional status (weight 50kg with height 166 cm).
Blood pressure was 120/80 mmHg, respiration 20, pulse
90, temperature 37.4oC. The conjunctiva were pale,
no jaundice on sclera. No lymph nodes enlargement.
Jugular venous pressure (JVP) within normal range.
There was systolic murmur grade I/II. Lung was within
normal range and no sign of cirrhosis. Abdomen
examination revealed palpation of tumor mass in
epigastrium to left hypocondrium region, hand boxer
with oval-rounded shape, slight cysteus-elastic, mobile
with clear margin and no pain. No hepatomegaly or
splenomegaly was found. Extremities revealed pale,
no palmar erythema. Rectal touché examination
showed black stools.
The laboratory examination on admission showed
hemoglobin 6.2 g/dl, hematocrit 25.1%, leukocyte 7,700/
mm3, platelet 253,000/mm3, LED 35/80, BT 2’3" and
CT 8’45". Peripheral blood result hypochrom micrositic
anemia, AST 38.2 U/L, ALT 16.7U/L, AP 200.8 U/L
and kidney function and amylase level in normal range.
Working diagnosis were epigastric tumor. Melena
had caused hypochrom micrositic anemia in this
patient. Clinical differential diagnosis:
1. Gastric tumor with ulceration
2. Left lobe liver abscess
Therapies were given such as octreotide, proton
pump inhibitor and blood transfusion.
Upper digestive tract endoscopy showed a
submucosal tumor, broad-based, centrally ulcerated,
projection of > 8 cm in the gastric corpus-antral wall
with erosive in LES esophagus (figure 1). Endoscopic
biopsies were negative for neoplastic changes,
H. pylori negative with serology IgG antiHp positive.
Abdominal ultrasound showed inhomogeneous
hypoechoic mass, clear margin, enlarge to the left with
size 11.7 x 6.2 cm; CT scan abdomen with contrast
was performed and showed large mass in epigastrium
to left hipochondrium, filling defect with soft tissue
density round/oval shape. There was no liver or spleen
enlargement. Conclusion of CT scan abdomen was
large gastric tumor (figure 2).
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At surgery, a large bulging tumor with surface  
erosion at posterior wall corpus was found. It was  
mobile and surounding mucosal tumor was still intact.  
No lymph node enlargement nor infiltration in the liver  
or spleen. Diagnostic surgery revealed gastric  
leiomyoma.  
Histolopatological studies on the surgical resection 
Figure 1.  Upper  digestive  tract  endoscopy  showed 
a submucosal tumor, centrally ulcerated, projection of > 5 cm in the 
gastric corpus-antral wall with erosive in LES esophagus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (A). Abdominal ultrasound showed inhomogeneous 
hypoechoic mass, clear margin enlarge to the left with size 11.7 x 
6.2 cm (B). CT scan abdomen with contrast was performed and 
showed large mass in epigastrium to left hipochondrium, filling 
defect with soft tissue density round/oval shape 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Resection specimen of a case of GIST shows a large 
bulging tumor with surface erosion at posterior wall corpus, 
mobile, intact mucosa around tumor 
 
 
 
 
 
 
 
 
 
Figure 4. Histologically, the tumor consist of densely packed spindle 
cell, atypia, pleomorfik with no evidence of mitotic activity 
 
The clinical diagnoses for the patient were 
submucosal gastric tumor suspect GIST with GERD 
grade B and peptic ulcer caused by H. pylori. Triple 
eradication therapy of Helicobacter pylori and 
followed by proton pump inhibitor agent. 
Consultation to digestive surgery and radiology 
department suggested to make distal gastrectomy with 
Billroth-I reconstruction. 
specimen revealed a gastrointestinal stromal tumour 
(GIST) of smooth muscle with spindle cell, atypia, 
pleomorfik with no evidence of mitotic activity.  
 One year after surgery the patient was improved  
with no signs of residual malignancy. However, 
metastases were later found in the liver in the next 
two years. The died due to metastatic cancer. 
DISCUSSION 
On admission, the patient had 5 years melena 
intermittent with history of chronic dyspepsia. 
Physical findings that showed the patient appears very 
pale with palpable of tumor mass in epigastric to the 
left hypochondrium. 
Blood transfusion was given to correct the anemia.  
The bleeding was minimized by given octreotide and  
Proton Pump Inhibitor agent. Upper digestive tract  
endoscopy showed a sub mucosal tumor, broad-based,  
centrally ulcerated, projection of > 5 cm in the gastric  
corpus-antral wall with erosive in LES esophagus.  
Biopsy specimen was negative for neoplastic changes  
and serology test for IgG antiHp was positive.  
Abdominal ultrasound and CT showed a large mass  
tumor enlarge to the left with size of 11.7 x 6.2 cm.  
 The source of bleeding for long period and  
intermittent originally from peptic ulcer where was  
active before due to H. pylori infection. The mucosal  
erosion at the base of the tumor because of tumor  
overgrowth had made pressure resulting necrosis and  
chronic bleeding. 
Grossly, GISTs are well-demarcated spherical  
masses that appear to arise from the muscularis  
propria layer of the GI wall. Intramural in origin, they  
often project exophytically and/or intraluminally, and  
they may have overlying mucosal ulceration. Larger  
GISTs nearly always outgrow their vascular supply,  
leading to extensive areas of necrosis and  
hemorrhage.6,9 
Submucosal  tumor  that  found at  Upper 
gastrointestinal  endoscopy  probably  was  
a mesenchymal tumor from GISTs group, where is 
differential diagnosis was tumor from smooth-muscle 
or neurogenic origin. GISTs account for approximately 
80% of GI mesenchymal tumors, which the stomach is 
the most common site (60-70%).2,8,15 
The understanding of mesenchymal neoplasms of  
the gastrointestinal tract has evolved dramatically over  
the last two decades since gastrointestinal stromal  
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tumor (GIST) was described as the most common
stromal tumor arising anywhere from the esophagus
to the ano-rectum. GISTs differ clinically and
pathogenetically from true leiomyosarcomas (very rare
in the GI tract) and leiomyomas. There was indicated
the majority that previosly diagnosed smooth muscle
tumors (SMT) actually belong to GIST.5,6,13,16
GISTs express more than 80% of the KIT protein,
gain-of-function mutations in the KIT or Platelet-
Derived Growth Factor Receptor alpha (PDGFRα)
gene is involved in oncogenesis and growth of
GISTs.10,17,18,19
Because of the uncertain biological behavior of
the GISTs an early surgical intervention is
recommended as well as therapeutic. Helicobacter
pylori eradication and cardiac condition was treated
to maintain optimal condition before surgery. Technique
gastrectomy Billroth-I showed large gastric leiomyoma
without metastases changes in accordance with USG
abdomen/CT Scan.
CT scan examination is being used with increasing
frequency in an attempt to diagnose primary and/or
metastasis GISTs before surgery. Double contrast
barium and CT Scan demonstrated an abnormality in
80% and 87-90% cases respectively.9,13
The most specific criterion for a diagnosis of GIST
by immunohistochemical examination of  c-KIT
(CD117) and presently account for 90% cases,
unfortunately the material not available in our
institution.
As noted previously, some authors specifically use
the term GIST to refer to only those mesenchymal
tumors that express CD117, whereas others believe
that the diagnosis can be made in the absence of CD117
positivity based on clinical and morphologic features.3,6,8
According to clinical manifestation and morphologic
features, diagnosis GIST of this case was made based
on:
- the patient’s age was 60 years old (typically
present in older individuals)
- occur in the stomach as gastric submucosal
tumor (60-70% cases)
- histological identified as highly cellular spindle
cell (70-80% cases)
The sign of high-risk malignant degeneration for this
patient were occurred because the size of the tumor
> 5 cm (size 11.7 x 6.2 cm). Necrotic area might cause
hemorrhage; although no metastases was found.
Condition of the patient 1 year after surgery was
improved, but the next two years liver metastases
ocurred and caused the patient die.
Regardless of the presentation, the disease-specific
survival rates with malignant GISTs are 69% at 1 year,
38-44% at 3 years, and 29-35% at 5 years.3
Surgical resection remains the mainstay of
treatment, as chemotherapy and radiation are
ineffective. In patients who had malignant primary
disease and who underwent complete gross resection
of the tumor, 40% had recurrence; 91% of
the patients died from the disease during the course of
one study. The disease-specific survival rate in this group
of patients was 88% at 1 year, 54-65% at
3 years, and 42-54% at 5 years. Recurrence is typical,
and the rate has been reported to be as high as 90% at
long-term follow-up.15
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